Literature DB >> 18690500

Glatiramer acetate is a treatment option in neutralising antibodies to interferon-beta-positive patients.

Marco Capobianco1, Annalisa Rizzo, Simona Malucchi, Francesca Sperli, Alessia Di Sapio, Alessandra Oggero, Mauro Zaffaroni, Angelo Ghezzi, Antonio Bertolotto.   

Abstract

Neutralising antibodies develop in 15% of interferon-beta (IFNbeta)-treated patients, causing the reduction of the clinical effects of the treatment. This is the first study that shows that switching patients from IFNbeta to glatiramer acetate (GA) in case of neutralising antibodies (NAb) positivity is effective in reducing relapse rate and in delaying the time to first relapse. In conclusion, our data suggest the use of GA in NAb-positive patients.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18690500     DOI： 10.1007/s10072-008-0945-y

Source DB:  PubMed          Journal:  Neurol Sci        ISSN： 1590-1874            Impact factor:   3.307


  10 in total

1.  Clinical course after change of immunomodulating therapy in relapsing-remitting multiple sclerosis.

Authors:  C Caon; M Din; W Ching; A Tselis; R Lisak; O Khan
Journal:  Eur J Neurol       Date:  2006-05       Impact factor: 6.089

Review 2.  Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis.

Authors:  P S Sørensen; F Deisenhammer; P Duda; R Hohlfeld; K-M Myhr; J Palace; C Polman; C Pozzilli; C Ross
Journal:  Eur J Neurol       Date:  2005-11       Impact factor: 6.089

3.  Biological markers of interferon-beta therapy: comparison among interferon-stimulated genes MxA, TRAIL and XAF-1.

Authors:  F Gilli; F Marnetto; M Caldano; A Sala; S Malucchi; M Capobianco; A Bertolotto
Journal:  Mult Scler       Date:  2006-02       Impact factor: 6.312

4.  Monthly corticosteroids decrease neutralizing antibodies to IFNbeta1 b: a randomized trial in multiple sclerosis.

Authors:  Carlo Pozzilli; Giovanni Antonini; Francesca Bagnato; Caterina Mainero; Valentina Tomassini; Emanuela Onesti; Roberta Fantozzi; Simona Galgani; Patrizio Pasqualetti; Enrico Millefiorini; Maria Spadaro; Frank Dahlke; Claudio Gasperini
Journal:  J Neurol       Date:  2002-01       Impact factor: 4.849

5.  Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory.

Authors:  A Bertolotto; S Malucchi; A Sala; G Orefice; P B Carrieri; M Capobianco; E Milano; F Melis; M T Giordana
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-08       Impact factor: 10.154

6.  Therapeutic outcome 3 years after switching of immunomodulatory therapies in patients with relapsing-remitting multiple sclerosis in Argentina.

Authors:  A Carrá; P Onaha; G Luetic; M Burgos; E Crespo; N Deri; M Halfon; G Jaacks; A López; V Sinay; C Vrech
Journal:  Eur J Neurol       Date:  2008-04       Impact factor: 6.089

7.  Fate of neutralizing and binding antibodies to IFN beta in MS patients treated with IFN beta for 6 years.

Authors:  Francesca Bellomi; Carolina Scagnolari; Valentina Tomassini; Claudio Gasperini; Andrea Paolillo; Carlo Pozzilli; Guido Antonelli
Journal:  J Neurol Sci       Date:  2003-11-15       Impact factor: 3.181

8.  Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis.

Authors:  Per Soelberg Sorensen; Christian Ross; Katja Maria Clemmesen; Klaus Bendtzen; Jette Lautrup Frederiksen; Kai Jensen; Ole Kristensen; Thor Petersen; Soren Rasmussen; Mads Ravnborg; Egon Stenager; Nils Koch-Henriksen
Journal:  Lancet       Date:  2003-10-11       Impact factor: 79.321

9.  Long-term follow-up of patients treated with glatiramer acetate: a multicentre, multinational extension of the European/Canadian double-blind, placebo-controlled, MRI-monitored trial.

Authors:  M Rovaris; G Comi; M A Rocca; P Valsasina; D Ladkani; E Pieri; S Weiss; G Shifroni; J S Wolinsky; M Filippi
Journal:  Mult Scler       Date:  2007-02-09       Impact factor: 6.312

10.  Neutralizing antibodies against IFN-beta in multiple sclerosis: antagonization of IFN-beta mediated suppression of MMPs.

Authors:  Francesca Gilli; Antonio Bertolotto; Arianna Sala; Francine Hoffmann; Marco Capobianco; Simona Malucchi; Tracy Glass; Ludwig Kappos; Raija L P Lindberg; David Leppert
Journal:  Brain       Date:  2003-11-07       Impact factor: 13.501
  10 in total
  4 in total

1.  Therapeutic strategies in childhood multiple sclerosis.

Authors:  Angelo Ghezzi
Journal:  Ther Adv Neurol Disord       Date:  2010-07       Impact factor: 6.570

2.  A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial.

Authors:  Tjalf Ziemssen; Ovidiu A Bajenaru; Adriana Carrá; Nina de Klippel; João C de Sá; Astrid Edland; Jette L Frederiksen; Olivier Heinzlef; Klimentini E Karageorgiou; Rafael H Lander Delgado; Anne-Marie Landtblom; Miguel A Macías Islas; Niall Tubridy; Yossi Gilgun-Sherki
Journal:  J Neurol       Date:  2014-08-14       Impact factor: 4.849

3.  Neutralizing antibodies and fatigue as predictors of low response to interferon-beta treatment in patients with multiple sclerosis.

Authors:  Philippe Manceau; Clotilde Latarche; Sophie Pittion; Gilles Edan; Jérôme de Sèze; Catherine Massart; Marc Debouverie
Journal:  BMC Neurol       Date:  2014-11-30       Impact factor: 2.474

4.  The transition from first-line to second-line therapy in multiple sclerosis.

Authors:  Jan Dörr; Friedemann Paul
Journal:  Curr Treat Options Neurol       Date:  2015-06       Impact factor: 3.972
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.